PURE — Pure Biosciences Balance Sheet
0.000.00%
- $5.91m
- $10.81m
- $2.20m
- 25
- 30
- 13
- 10
Annual balance sheet for Pure Biosciences, fiscal year end - July 31st, USD millions except per share, conversion factor applied.
2021 July 31st | 2022 July 31st | 2023 July 31st | 2024 July 31st | 2025 July 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 2.39 | 3.39 | 1.09 | 0.349 | 0.334 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0.368 | 0.201 | 0.285 | 0.298 | 0.474 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 3.2 | 3.86 | 1.6 | 0.805 | 1.05 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0.74 | 0.62 | 0.221 | 0.013 | 0.011 |
| Net Intangible Assets | |||||
| Total Assets | 4.3 | 4.48 | 1.82 | 0.818 | 1.06 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Current Liabilities | 0.97 | 0.575 | 0.532 | 0.733 | 0.938 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Liabilities | 0.97 | 0.575 | 1.55 | 3.68 | 6.17 |
| Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | 3.33 | 3.91 | 0.272 | -2.86 | -5.12 |
| Total Liabilities & Shareholders' Equity | 4.3 | 4.48 | 1.82 | 0.818 | 1.06 |
| Total Common Shares Outstanding |